Allergan expands partnership with McCann Healthcare for new product launch

Latisse is the first drug to promote eyelash growth. The product is expected to roll out in the third quarter of this year in key Asian markets including Singapore.

In addition to Latisse, the McCann Worldgroup agency handles the advertising for other Allergan products including Botox and Juvederm. 

Gloria Ma, regional marketing manager Asia Pacific for Allergan, said: “Latisse fulfills a significant and previously unmet need in the medical aesthetic marketplace. We estimate global peak sales of Latisse could exceed $500 million per year.”

Rohit Sahgal, managing director, McCann Healthcare Worldwide Singapore, added: “This is a dynamic time for us and the Singapore healthcare communications industry, where more regional-oriented clients are looking to reinforce their brand positioning in the market. McCann Healthcare Worldwide Singapore has been partnering Allergan's regional facial aesthetics team for over two years and now with Latisse, we're entering a new and exciting category that will benefit millions of consumers everywhere.”